Email: cspc@cspc.cn
News
August 22, 2025
Share:
Previous: VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR KN026 (ANBENITAMAB INJECTION) ACCEPTED BY THE NMPA
Next: VOLUNTARY ANNOUNCEMENT - DUPILUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us